Humacyte, Inc. (HUMA): Shareholders' Equity
$3.11M
As of 2025-12-31
$31.26M
As of 2026-06-30
-70.2%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.11M | n/m | 2026-03-27, Balance as of period end |
| 2024-12-31 | -$52.67M | n/m | 2026-03-27, Balance as of period end |
| 2023-12-31 | $13.55M | -88.4% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $116.93M | -4.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $122.17M | n/m | 2023-03-24, Balance as of period end |
| 2020-12-31 | -$350.32M | n/a | 2022-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $3.11M | n/m |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $53.55M | n/m |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | -$32.19M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | $1.23M | -50.1% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $8.10M | -18.8% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $7.99M | -94.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$187.76M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $1.92B | -0.5% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $752.60M | +2.6% |
Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗